https://www.selleckchem.com/products/Y-27632.html
[This corrects the article DOI 10.3389/fphys.2020.00547.]. Sacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slower than expected. Our objective was to develop a score predicting the super-response to SV in HF outpatients. This is a retrospective analysis of 185 consecutive patients prescribed SV from two tertiary hospitals between September 2016 and Februa
Like
Comment
Share
